

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## Clark & Elbing LLP

101 Federal Street  
Boston, MA 02110

Telephone 617-428-0200  
Facsimile 617-428-7045  
617-428 7046

Date: March 29, 2004

To: Commissioner for Parents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Facsimile No: 703-746-9195

From: Paul T. Clark

Re: U.S. Serial No. 10/698,572  
"TREFOIL DOMAIN-CONTAINING POLYPEPTIDES AND USES  
THEREOF"  
Art Unit 1645  
Our Reference: 50206/012002

Pages: 6, including this one.

---

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

---

PATENT  
ATTORNEY DOCKET NO. 50206/012002

Certificate of Facsimile Transmission	
Date of Transmission: <u>March 29, 2004</u>	
I hereby certify that this correspondence is being transmitted by facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450; Facsimile No. 703-746-9195.	
<u>Kathy Meuse</u> Printed Name of Person Sending Transmission	<u>Kathy Meuse</u> Signature of Person Sending Transmission

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Nicholas P. Barker et al.	Art Unit:	1645
Serial No.:	10/698,572	Examiner:	Not Yet Assigned
Filed:	October 31, 2003	Customer No.:	21559
Title:	TREFOL DOMAIN-CONTAINING POLYPEPTIDES AND USES THEREOF		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PETITION TO CORRECT FILING RECEIPT

Applicant requests that the enclosed filing receipt be corrected as follows:

Domestic Priority Data as Claimed by Applicant should read:


This application is a CIP of 10/131,063 4/24/2002 which claims benefit of 60/286,240 4/24/2001  
and a CIP of 10/266,069 10/7/2002 which claims benefit of 60/327,673 10/5/2001  
and a CIP of 10/235,238 9/5/2002 which claims benefit of 60/317,657 9/6/2001  
and a CIP of 10/208,968 7/31/2002 which claims benefit of 60/309,238 7/31/2001  
and a CIP of 10/305,747 11/27/2002 which claims benefit of 60/333,836 11/28/2001  
and a CIP of 10/397,953 3/26/2003 which claims benefit of 60/367,574 3/26/2002.  
This application 10/698,572 claims benefit of 60/422,708 10/31/2002

For the Examiner's convenience, a copy of the first page of the application as filed is enclosed.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: March 29, 2004

  
\_\_\_\_\_  
Paul T. Clark  
Reg. No. 30,162

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22304-1450  
www.uspto.gov

APPL NO.	FLING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/698,572	10/31/2003	1645	626	50206/012002	14	42	4

21559  
CLARK & ELBING LLP  
101 FEDERAL STREET  
BOSTON, MA 02110

CONFIRMATION NO. 1119

## FILING RECEIPT



\*OCDC000001 1933422\*

Date Mailed: 02/19/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Nicholas P. Barker, Southborough, MA;  
Daniel K. Podolsky, Wellesley, MA;

### Domestic Priority data as claimed by applicant

This application is a CIP of 10/131,063 04/24/2002  
which claims benefit of 60/286,240 04/24/2001  
WHICH ~~AND~~ claims benefit of 60/327,673 10/05/2001  
WHICH ~~AND~~ claims benefit of 60/317,657 09/06/2001  
WHICH ~~AND~~ claims benefit of 60/309,238 07/31/2001  
WHICH ~~AND~~ claims benefit of 60/333,836 11/28/2001  
WHICH ~~AND~~ claims benefit of 60/367,574 03/26/2002  
This application 10/698,572  
claims benefit of 60/422,708 10/31/2002

AND A CIP OF 10/266,069 10/7/2002  
AND A CIP OF 10/235,238 9/5/2002  
AND A CIP OF 10/208,968 7/31/2002  
AND A CIP OF 10/305,747 11/27/2002  
AND A CIP OF 10/397,953 3/26/2003

## Foreign Applications

**If Required, Foreign Filing License Granted: 02/18/2004**

**Projected Publication Date:** To Be Determined - pending completion of Missing Parts

**Non-Publication Request: No**

**Early Publication Request: No**

**\*\* SMALL ENTITY \*\*****Title**

Trefoil domain-containing polypeptides and uses thereof

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PATENT  
ATTORNEY DOCKET NO: 50206/012002

**TREFOIL DOMAIN-CONTAINING POLYPEPTIDES  
AND USES THEREOF**

5

[0001] This application is a continuation-in-part of U.S. Application 10/131,063 (filed April 24, 2002), which claims benefit of U.S. Provisional Application No. 60/286,240 (filed April 24, 2001), U.S. Application 10/266,069 (filed October 7, 2002), which  
10 claims benefit of U.S. Provisional Application No. 60/327,673 (filed October 5, 2001), U.S. Application 10/235,238 (filed September 5, 2002), which claims benefit of U.S. Provisional Application No. 60/317,657 (filed September 6, 2001), U.S. Application 10/208,968 (filed July 31, 2002), which claims benefit of U.S. Provisional Application No. 60/309,238 (filed July 31, 2001), U.S. Application 10/305,747 (filed  
15 November 27, 2002), which claims benefit of U.S. Provisional Application No. 60/333,836 (filed November 28, 2001), and U.S. Application 10/397,953 (filed March 26, 2003), which claims benefit of U.S. Provisional Application Nos. 60/367,574 (filed March 26, 2002). This application claims benefit of the filing date of U.S. Provisional Application No. 60/422,708 (filed October 31, 2002), hereby incorporated  
20 by reference.

**Field of the Invention**

[0002] This invention related to the treatment of epithelial cell lesions.

25

**Background of the Invention**

[0003] Epithelial tissues line the surfaces of the body and internal organs and serve to protect them from the external environment. For instance, epithelial cells of the skin prevent or reduce desiccation and the harmful effects of UV radiation, aid in temperature homeostasis, and are the first line of defense to protect against chemical  
30 and thermal insults and infections by microbial pathogens. However, because these